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Abstract
Oncogenic transformation in Ewing sarcoma tumors is driven by the fusion oncogene EWS-FLI1. 
However, despite the well-established role of EWS-FLI1 in tumor initiation, the development of 
models of Ewing sarcoma in human cells with defined genetic elements has been challenging. 
Here, we report a novel approach to model the initiation of Ewing sarcoma tumorigenesis that 
exploits the developmental and pluripotent potential of human embryonic stem cells. The 
inducible expression of EWS-FLI1 in embryoid bodies, or collections of differentiating stem cells, 
generates cells with properties of Ewing sarcoma tumors, including characteristics of 
transformation. These cell lines exhibit anchorage-independent growth, a lack of contact inhibition 
and a strong Ewing sarcoma gene expression signature. Furthermore, these cells also demonstrate 
a requirement for the persistent expression of EWS-FLI1 for cell survival and growth, which is a 
hallmark Ewing sarcoma tumors.
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INTRODUCTION
Ewing sarcoma is an aggressive bone and soft tissue tumor that affects children and young 
adults1. Ewing sarcoma is defined by a recurrent chromosomal translocation between the 
EWSR1 gene and various ETS genes2. The most common fusion, EWS-FLI1, is present in 
85% of cases. In each case, the transcriptional activation domain from EWSR1 is fused to 
the DNA-binding domain of an ETS transcription factor, consistent with experimental 
evidence suggesting that EWS-FLI1 functions as an aberrant transcription factor3–6. 
Importantly, Ewing sarcoma tumors are dependent on EWS-FLI1 and require the persistent 
expression of this oncogene to maintain the transformed phenotype7–10.
Additional genomic alterations in Ewing sarcoma tumors, other than the EWS-FLI1 
translocation, are often minimal11–14. However, some tumors do exhibit mutations in TP53, 
deletions of the CDKN2A locus or mutations in STAG211–13. Specifically, mutations in 
TP53 and STAG2 occur in ~5–10% and ~15–20% of tumors, respectively11–13,15. 
Interestingly, almost all Ewing sarcoma cell lines exhibit mutations in p53, or members of 
the p53 pathway, which has led to the hypothesis that loss of p53 is required for the in vitro 
culture of Ewing sarcoma cells16.
Although the initiating oncogene in Ewing sarcoma, EWS-FLI1, was first identified over 
twenty years ago, the cell-of-origin17 in Ewing sarcoma is still unknown and a source of 
considerable debate. There is experimental support for both neural crest and mesenchymal 
origins in Ewing sarcoma18–21. Multiple experiments have demonstrated that the effects of 
EWS-FLI1 expression are strongly dependent on the cellular background. For example, 
EWS-FLI1 causes a p53-dependent growth arrest and toxicity in human and mouse 
fibroblasts, but is tolerated in some human mesenchymal and neural crest cells18–23. 
However, mesenchymal and neural crest cells, unlike Ewing sarcoma tumors, do not require 
EWS-FLI1 for growth and, thus, fail to recapitulate the critical hallmark of the dependency 
on persistent EWS-FLI1 expression for cell survival.
One significant difficulty in developing a model system of Ewing sarcoma has been the 
uncertainty regarding the cell-of-origin and the resulting lack of an appropriate cell type in 
which to study the EWS-FLI1 oncogene. To circumvent this problem, we have developed a 
novel approach to model Ewing sarcoma that exploits the differentiation potential of human 
stem cells and the cellular diversity of embryoid bodies. Embryoid bodies, which are three-
dimensional aggregates of differentiating stem cells, contain cells from all three germ cell 
layers and are the in vitro equivalent of a teratoma. Our hypothesis was that embryoid 
bodies, due to their cellular diversity, could contain an appropriate cell-of-origin for Ewing 
sarcoma. In this work, we demonstrate that the doxycycline-inducible expression of EWS-
FLI1 in embryoid bodies derived from human embryonic stem cells (hESC) with 
knockdown of p53 generates cells with an Ewing sarcoma-like phenotype, including 
properties of transformation and dependency on persistent EWS-FLI1 expression for 
survival.
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RESULTS
Human embryoid bodies are permissive for EWS-FLI1 expression
The molecular pathogenesis of Ewing sarcoma remains poorly understood, despite the 
underlying association with the EWS-FLI1 oncogene16,24. In order to develop a model of 
Ewing sarcoma with defined genetic elements in human cells, we used a lentiviral vector to 
generate H1 human embryonic stem cells that express EWS-FLI1 (EF1) and green 
fluorescent protein (GFP) under the control of a doxycycline-inducible element (pLVX-EF1-
IRES-GFP). This lentiviral vector was also modified, as described in the Materials and 
Methods section, to constitutively express an shRNA targeting p53 because loss of this 
tumor suppressor is relevant to a subset of Ewing sarcoma tumors. Data are shown for the 
modified H1 stem cell line (referred to as EF cells), but similar results were obtained with an 
independent stem cell line (WA25, WiCell Research Institute) (Supplemental Figure S1).
A schematic of the differentiation protocol is shown in Figure 1A. The EF cells, when 
cultured as embryoid bodies (Supplemental Figure S2A) under non-adherent conditions, 
spontaneously differentiate to cells from all three germ layers, as demonstrated by RT-qPCR 
for lineage specific genes (Supplemental Figure S2B). Addition of doxycycline to the 
embryoid body cultures after 7 days of culture results in the expression of EWS-FLI1, as 
demonstrated by western blot analysis (Figure 1B). Similarly, western blot analysis also 
demonstrates constitutive knockdown of p53 (Figure 1C). Dissociation of the embryoid 
bodies with trypsin followed by flow cytometry for GFP shows an approximately 100-fold 
range of expression levels in the embryoid body cells (Supplemental Figure S2C).
Cell Phenotype
After 10–14 days of suspension culture the embryoid bodies were plated on gelatin-coated 
plates for monolayer culture to assay for transformation. In the absence of doxycycline, 
adherent cells with a fibroblast morphology (Figure 1D), referred to as EFFib cells, grew out 
of the embryoid bodies and could be expanded and propagated in culture. These cells were 
non-immortalized and could be grown in vitro for approximately 6–8 weeks before 
undergoing senescence. In the presence of doxycycline, rare colonies of cells with a unique 
morphology (Figure 1E), referred to as EF+ cells, emerged after several weeks of culture, 
usually in a background of more fibroblast-like cells. These EF+ cells exhibited a round 
shape, rather than the more elongated, spindle shape of the EFFib cells. Repeated passaging 
of these cells in the presence of doxycycline (see Material and Methods section) resulted in 
progressive enrichment for the round cells and, eventually, a homogenous population of 
cells. The expression level of EWS-FLI1 in these cells was comparable to the levels in the 
ES cell lines A673 and TC32 (Figure 1F). The EF+ cells grow with a doubling time of 
approximately 28 hours (Figure 1G) and have now been in continuous cell culture for >10 
months without undergoing senescence. In contrast to the EF+ cells, addition of doxycycline 
to the EFFib cells results in a significant decrease in proliferation, consistent with reports that 
EWS-FLI1 induces a growth arrest in fibroblast cells (Supplemental Figure S3)22.
The karyotype of the parental H1 embryonic stem cells is 46, XY, which is maintained by 
the EFFib cells (Supplemental Figure S4A). Karyotype results from the EF+ cells, however, 
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were more variable. In one experiment, the EF+ cells showed a stable karyotype identical to 
the parental cells (Supplemental Figure S4B and S4E). However, a second experiment 
showed a tetraploid karyotype, as assessed by G-band karyotype (Supplemental Figure S4C 
and S4F) and interphase fluorescent in situ hybridization (FISH) (Supplemental Figure 
S4D). This tetraploid karyotype was observed at passages 15 and 37, although within this 
population of tetraploid cells there were some cells with gains and losses of individual 
chromosomes (data not shown). This is consistent with data demonstrating that tetraploidy 
can lead to chromosomal instability25.
Immunophenotype
Ewing sarcoma tumors can express both mesenchymal markers, including CD73 and 
CD105, and neural crest markers, including CD27126,27. We found that the EF+ cells, 
similar to Ewing sarcoma tumors, express the markers CD73, CD105 and CD271 (Figure 
2A). Multiparameter flow cytometry was used to confirm that individual EF+ cells were 
positive for both CD105 and CD271 (Figure 2B). In contrast, the EFFib cells express the 
mesenchymal cell markers CD73 and CD105, consistent with the differentiation protocol 
used in this study and their fibroblast-like morphology (Figure 1D), but do not express the 
neural crest cell marker CD271. None of the cells express CD34, a hematopoietic cell 
marker.
Common diagnostic markers in Ewing sarcoma that may reflect lineage and/or 
transformation include CD99 and c-Kit. CD99 is a highly sensitive, but not specific, marker 
for Ewing sarcoma that is also expressed on mesenchymal cells28. The c-Kit receptor is 
expressed in 30–50% of patient-derived Ewing sarcoma tumors, but is not expressed in 
mesenchymal cells29,30. The EFFib cells express CD99, but do not express c-Kit (Figure 2C). 
The EF+ cells, on the other hand, express both CD99 and c-Kit (Figure 2A), recapitulating 
the characteristics of primary Ewing sarcoma tumors. Although CD99 is a sensitive marker 
for Ewing sarcoma, data suggest that its expression is not strongly regulated by EWS-
FLI17,8,28. In agreement with this data, the removal of doxycycline from the EF+ cells had 
only a minimal effect on CD99 expression, but did lead to a 10-fold loss of c-Kit expression 
(Figure 2D). In summary, the cell surface marker analysis of the EF+ cells was highly 
consistent with an Ewing sarcoma tumor expression pattern.
EF+ cells exhibit properties of transformation
We removed doxycycline from the EF+ cells to evaluate for dependency on continued EWS-
FLI1 expression for growth, a feature of most Ewing sarcoma cells lines. RT-qPCR (Figure 
3A) and western blotting (Figure 3B) were used to verify the rapid and complete depletion 
of EWS-FLI1 after drug removal. A morphological change was noted in the cells 
approximately three-to-five days after doxycycline removal, with the EF− cells exhibiting a 
larger, flatter and more spindle-shaped morphology (data not shown). After doxycycline 
removal, the EF− cells exhibit decreased proliferation (Figure 3C). Notably, EdU labeling 
demonstrated a complete lack of S-phase cells after four days of doxycycline removal 
(Figure 3D). Culture for additional days in the absence of doxycycline resulted in the loss of 
cell adhesion and cell death. This coincided with the expression of caspase-3, a marker of 
apoptosis, in the EF− cells (Figure 3E). Recent work has demonstrated that Ewing sarcoma 
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cell lines exhibit sensitivity to PARP1 inhibitors, including olaparib31,32. The EF+ cells show 
enhanced sensitivity to olaparib treatment (IC50 2.37 μM; 95% confidence interval 2.1–2.7 
μM) relative to the EFFib cells (IC50 54.2 μM; 95% confidence interval 23.6–124.4 μM) 
(Figure 3F). Similarly, the EF+ cells are also more sensitive than the EFFib cell to treatment 
with additional drugs with reported lethality toward Ewing sarcoma cell lines, including 
YK-4-279 (inhibitor of the interaction between RNA helicase A and EWS-FLI1), 
mithramycin (DNA-binding drug) and LY294002 (PI3K pathway inhibitor) (Supplemental 
Figure S5)33–35.
The EF+ cells, unlike the EFFib cells, exhibit a lack of contact inhibition. After culture for 
fourteen days, staining with methylene blue revealed many dense foci of EF+ cells, whereas 
the EFFib cells maintained a monolayer growth pattern with contact inhibition, expected for 
non-transformed fibroblast cells (Figure 4A). The EF+ cells also exhibited anchorage-
independent growth and formed colonies in a soft agar assay (Figure 4B). In contrast, the 
EFFib control cells did not form colonies in soft agar. Despite exhibiting hallmarks of 
transformation, the EF+ cells did not form tumors when injected subcutaneously into 
immunocompromised mice in a xenograft experiment (see Material and Methods).
Since the EF+ cells were created using lentiviral vectors we were able to assess the EF+ cells 
lines for a clonal growth pattern, a common characteristic of transformed cells, using 
lentiviral integration site analysis and a genome walking approach. The EF+ cells were 
generated using two lentiviral vectors, one expressing rtTA and the other expressing EWS-
FLI1 under the control of the tetracycline responsive element (TRE) promoter. Integration 
analysis of the parental, EF stem cells shows an indistinct pattern consistent with multiple 
lentiviral integration sites, or clones (Figure 4C). The EF+ cells at passage 4 also 
demonstrate a pattern consistent with multiple clones, but there is the early appearance of a 
limited number of dominant bands, or integration sites, in each digestion library. By passage 
21, however, the integration analysis shows a very discrete pattern consistent with a limited 
number of clones.
EF+ cells exhibit a highly specific Ewing sarcoma gene expression profile
Next we addressed whether the EF+ cells exhibited an Ewing sarcoma gene expression 
signature and, if so, whether our doxycycline-inducible, isogenic system would be 
advantageous in identifying gene expression changes related to EWS-FLI1. Unsupervised 
hierarchical clustering was performed with the EF+ cells and 88 cancer cell lines across 12 
different tumor types (Figure 5A). Notably, the EF+ cells clustered most closely with the 
Ewing sarcoma cell lines relative to the other sarcomas and tumor types.
The gene expression of the EF+ cells was then compared to both the EF− cells and the EFFib 
cells. The EF+ versus EF− analysis is the most direct comparison, but the advantage of the 
EF+ versus EFFib comparison is that the EFFib cells proliferate normally, unlike the EF− cells 
that undergo cell cycle arrest and apoptosis after the removal of doxycycline. Furthermore, a 
number of other studies have compared the gene expression of Ewing sarcoma tumors to 
mesenchymal cells, the lineage of the EFFib cells based on immunophenotype (Figure 2C), 
in order to identify genes regulated by EWS-FLI16,20,36,37. A potential limitation of this 
comparison, though, is that the EF+ and EFFib cells may derive from different precursor 
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cells. However, we anticipated that the intersection of these different gene lists could be 
useful for identifying a core set of genes regulated by EWS-FLI1.
A comparison of gene expression between EF+ and EF− cells, four days after doxycycline 
removal, revealed 659 genes with differential expression (Fold > 3 and FDR < 0.01) 
(Supplemental Table S3). A total of 1175 genes (Fold > 3 and FDR < 0.01) were 
differentially expressed between the EF+ and EFFib cells (Supplemental Table S4). 
Importantly, both analyses identified the upregulation and downregulation of well-validated 
targets of EWS-FLI1, including NR0B13, NKX2-25,7, CCND138, BCL11B39, EZH240, and 
GRP41. Furthermore, in both comparisons, multiple genes that are highly expressed in 
Ewing sarcoma tumors, including NR0B13, GRP41 and NPY42, demonstrated greater than a 
50-fold change in expression level, validating the utility of this inducible, isogenic and dual 
comparison approach. Select genes were validated with RT-qPCR (Figure 5B) and the 
twenty-five most highly upregulated genes from each comparison are shown in Table 1. 
Notably, these gene expression signatures are also significantly enriched in the Ewing 
sarcoma cell lines in the Cancer Cell Line Encyclopedia (Broad Institute) compared to the 
~1000 other tumor cell lines, as assessed using the analysis tool Enrichr43 (Table 2 and 
Supplemental Table S5).
To more systematically evaluate our gene expression results, we used gene set enrichment 
analysis (GSEA) to determine whether a “core EWS-FLI1 gene expression signature,” 
generated by Hancock et al. using a meta-analysis approach that combined data from 
thirteen independent studies, was enriched in our data sets44. The Hancock et al. upregulated 
and downregulated EWS-FLI1 gene sets (Figure 5C and 5D) were significantly (FDR q-
value = 0.0) enriched in the EF+ cells in both of our gene expression comparisons. A second 
set of EWS-FLI1 core genes, generated by Kauer at al. from different experimental data than 
the Hancock et al. data, showed similar enrichment in the EF+ cells (Supplemental Figure 
S6)36.
GSEA was also performed using gene sets from the MSigDB collection, which is a 
collection of annotated gene sets available for use with GSEA45. Multiple, published EWS-
FLI1 gene sets in this collection, including RIGGI_EWING, STAEGE_EWING, 
ZHANG_TARGETS_OF_EWSR1_FLI1, and MIYAGAWA_TARGETS_OF_EWSR1_ETS, 
showed significant (FDR q-value = 0.0) enrichment in our expression data (Figure 5C and 
5D). In addition to these EWS-FLI1 data sets, the EF+ cells also showed significant 
enrichment for other gene sets in the MSigDB (Supplemental Table S6 and S7). In the EF+ 
versus EF− comparison, the most enriched gene sets from the gene ontology collection were 
related to the cell cycle and mitosis (Supplemental Table S6), which is likely reflective of the 
arrest in cell proliferation that is observed after the removal of doxycycline (Figures 3C and 
3D). In the EF+ versus EFFib comparison, there was significant enrichment (FDR q-value = 
0.0) for gene ontology sets related to the mitochondria, oxidative phosphorylation, 
mitochondria and electron transport (Supplemental Table S7).
Next, we evaluated whether the differentially expressed genes identified in our inducible and 
isogenic system were enriched in Ewing sarcoma cell lines and primary tumors. In the same 
analysis, we also compared how our gene sets performed relative to the Hancock et al. gene 
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set. Gene expression data from the Cancer Cell Line Encyclopedia (CCLE, http://
www.broadinstitute.org/ccle/home) was used to compare ten Ewing sarcoma cells lines to 88 
other cell lines46. These other cell lines included all sarcoma samples in the CCLE, as well 
as a spectrum of other tumor types (Supplemental Table S8). GSEA was performed using 
the upregulated genes from EF+ versus EF−, EF+ versus EFFib and Hancock et al. All gene 
sets showed significant enrichment in the Ewing sarcoma cell lines relative to the other 
tumor types (Figure 6A). The normalized enrichment scores (NES), which allow for the 
comparison of analysis results across gene sets, for the EF+ versus EF−, EF+ versus EFFib 
and Hancock et al. gene sets were 2.31, 2.35 and 2.15, respectively.
The gene list from EF+ versus EF− was then compared to the gene list from EF+ versus 
EFFib to identify an overlapping set of genes with differential expression, referred to as the 
EF Overlap gene set (Figure 6B and Supplemental Table S9). This set contains 273 genes 
and includes many genes with established roles and/or expression profiles in Ewing 
sarcoma, including BCL11B39, CCND138, NKX2-25,7, NR0B13, NPY42, NPY1R20, 
STEAP147. The EF Overlap upregulated gene list exhibits significant enrichment (FDR q-
value = 0.0; NES 2.31) in the Ewing sarcoma cell lines compared to the other tumor types 
(Figure 6C). There were forty-three upregulated genes in common between the EF Overlap 
and Hancock et al. gene sets (Figure 6B, Supplemental Table S10). This included the well-
validated genes NR0B13, NKX2-25,7 and EZH240. The next question we addressed was 
whether these common genes were primarily responsible for the enrichment of our gene set 
in the Ewing sarcoma cell lines so we repeated the GSEA analysis using the set of 
upregulated genes that was unique to the EF Overlap list and not included on the Hancock et 
al. list. These unique genes (EF Unique, Supplemental Table S11) were significantly (FDR 
q-value = 0.0; NES 2.22) enriched in the Ewing sarcoma cell lines compared to the other 
tumor types (Figure 6D). Similar results were obtained when the EF gene lists were 
compared to the Kauer et al. gene list (data not shown)36.
Finally, using published microarray data, we evaluated whether the EWS-FLI1 gene sets 
identified in our system were significantly enriched in primary Ewing sarcoma tumors48 
relative to primary osteosarcoma tumors49 (Figure 6E). Again, similar to the cell lines 
results, we observed significant (FDR q-value = 0.0–0.003) enrichment of our gene sets in 
the primary Ewing sarcoma tumor expression data. Overall, these gene expression data 
provide further evidence for an Ewing sarcoma-like phenotype for the EF+ cells and also 
identify new genes that are potentially regulated by EWS-FLI1.
DISCUSSION
The use of model organisms, including mice and zebrafish, has been critical in exploring the 
role of the cell-of-origin in tumorigenesis (reviewed in Visvader et al. 17). In human cells, 
however, it is often difficult to express an oncogene in a specific cell type at the appropriate 
developmental stage. In this work, we demonstrate that the expression of EWS-FLI1, in 
combination with the knockdown of p53, in embryoid bodies generates cells that 
recapitulate a number of important aspects of Ewing sarcoma biology. We chose to 
knockdown p53 in our model system because mutations in this tumor suppressor occur in 
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vivo in a subset of patients and, importantly, almost all Ewing sarcoma cell lines exhibit 
mutations in p53.
The EF+ cells demonstrate a dependency on EWS-FLI1 expression for cell survival, or 
oncogene addiction. To our knowledge, this is the first model of Ewing sarcoma in human 
cells that exhibits a requirement for EWS-FLI1 expression. The removal of doxycycline 
from the EF+ cells leads to cell cycle changes and apoptosis, which parallels what occurs 
after knockdown of EWS-FLI1 in Ewing sarcoma cell lines8,24. The EF+ cells also exhibit 
other properties of transformation. This includes both anchorage-independent growth and a 
lack of contact inhibition. Furthermore, the EF+ cells, relative to the EFFib cells, exhibit 
significantly enhanced sensitivity to the PARP inhibitor olaparib, which is also reported for 
Ewing sarcoma cells lines relative to other cancer cell lines and non-transformed cells31,32. 
This drug toxicity data suggest that the EF+ and EFFib cells may be useful in small molecule 
and/or RNAi screens to identify novel compounds/genes with selective toxicity to Ewing 
sarcoma cells.
In one experiment, the EF+ cells became tetraploid with a complete duplication of their 
chromosome content. Tetraploidy is a common feature of tumors and transformed cells. A 
recent study that included a spectrum of eleven different tumor types identified whole 
genome doublings in 37% of tumors50. In Ewing sarcoma, tetraploidy has been reported in 
both primary tumors and cell lines51–53. Although the impact of genome doubling in Ewing 
sarcoma tumors is not known, tetraploidy is also consistent with a transformed phenotype in 
the EF+ cells. Notably, in our system, the knockdown of p53 may have also contributed to 
the propagation of the EF+ tetraploid cells since p53 is a well-described barrier to 
tetraploidy54.
Although the EF+ cells exhibit multiple characteristics of transformation, the cells did not 
form tumors in immunocompromised mice. Importantly, the engraftment efficiencies in 
mice of primary, patient-derived tumors is highly variable, with some human tumors failing 
to form any tumors in mice55. Consequently, the inability of the EF+ cells to form xenograft 
tumors does not exclude the possibility that the cells are transformed. However, additional 
reasons could also explain the inability of the EF+ cells to form tumors in vivo. For example, 
the lack of xenograft tumors could reflect the need for additional genetic events, such as the 
loss of STAG2 or trisomy 8, for growth of the cells in the mouse.
The gene expression experiments identified many known targets of EWS-FLI1, including 
NR0B1, NKX2-2, and BCL11B. A number of these differentially regulated genes exhibit 
>50-fold changes in expression level, likely reflecting the advantages of an isogenic system 
and the ability to tightly regulate the expression of EWS-FLI1 using doxycycline. Although, 
there is not a gold standard for an Ewing sarcoma gene expression signature, the 
differentially expressed genes identified in this study are significantly enriched for EWS-
FLI1 “core genes,” as identified in the analysis of multiple studies36,44.
In addition to Ewing sarcoma gene sets, GSEA also identified enrichment for cell cycle gene 
sets in the EF+ versus EF− comparison. Cell cycle deregulation is well described in Ewing 
sarcoma (reviewed in Kowalewski et al.56) and enrichment of cell cycle genes has been 
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identified in other gene expression experiments36. Cyclin D1, for example, is an established 
target of EWS-FLI1 and this gene was upregulated 8-fold in the EF+ cells relative to the EF− 
cells 38. However, the alteration in the expression of some of the other cell cycle genes is 
likely an indirect effect due to the arrest in proliferation seen after the removal of 
doxycycline (Figure 3D), rather than direct targeting by EWS-FLI1. This conclusion is 
supported by the observation that the strong enrichment for the cell cycle and mitotic gene 
sets, described for the EF+ versus EF− comparison, was not observed in the EF+ versus 
EFFib comparison, where both the EF+ and EFFib cells proliferate normally. By contrast, 
Cyclin D1 remains overexpressed (8-fold) in the EF+ cells compared to the EFFib cells, as 
might be predicted for a direct target of EWS-FLI1 38.
GSEA analysis also identified enrichment for oxidative phosphorylation and mitochondrial 
gene sets in the EF+ versus EFFib comparison. Alterations in metabolism are well described 
in cancer cells57. Furthermore, Lin28b, an important regulator of cellular metabolism58, is 
3.5-fold and 40-fold overexpressed in the EF+ cells relative to the EF− and EFFib cells, 
respectively. Importantly, the overexpression of Lin28b in Ewing sarcoma cell lines, relative 
to mesenchymal cells, and alterations in the level of Let-7a, a known target of Lin28, have 
also been reported in Ewing sarcoma cell lines59.
Many known targets of EWS-FI1, as well as novel genes, were identified in our analysis. 
Notably, when tested using a set of Ewing sarcoma cell lines and primary tumors our gene 
expression signatures perform better, based on NES scores, than a core Ewing sarcoma gene 
signature generated from a meta-analysis of thirteen studies. Our isogenic and inducible 
system avoids the experimental variation that is likely one cause of the only modest overlap 
of Ewing sarcoma gene signatures that are generated in different studies44. Furthermore, the 
genes that are unique to our gene expression data are still significantly enriched in Ewing 
sarcoma tumor cell lines even if the common genes are removed from the analysis. This 
suggests that these “unique” genes may have a role in Ewing sarcoma pathophysiology.
In summary, we have developed a novel approach to model tumorigenesis in human cells 
that utilizes the developmental and pluripotent potential of stem cells. We anticipate these 
model cell lines and the gene expression data will be useful for investigating the 
pathophysiology of Ewing sarcoma. Furthermore, the cell-of-origin question in Ewing 
sarcoma could be investigated in a modification our approach by using lineage specific 
promoters, rather than the doxycycline-inducible promoter. We also expect that it may be 
possible to extend our experimental approach to additional types of cancer and to other 
biological systems where the cell-of-origin is critical.
MATERTIALS AND METHODS
Ethics statement
The Embryonic Stem Cell Research Oversight Committee at the Dana-Farber Cancer 
Institute approved the stem cell experiments. The Institutional Animal Care and Usage 
Committee at the Dana-Farber Cancer Institute approved the animal studies.
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Stem cell culture
Cell lines were maintained at 37°_C in a 5% CO2 atmosphere. H1 stem cells (WA01, WiCell 
Research Institute) were cultured in mTESR1 media (Stemcell Technologies) on plates 
coated with matrigel (BD Biosciences). The stem cells were passaged every 4–6 days using 
versene (Gibco).
Embryoid body formation
Embryoid bodies were formed using AggreWell plates (Stemcell Technologies) according to 
the manufacturer’s instructions. Briefly, stem cells were collected using Accutase (Stemcell 
Technologies), centrifuged at 300 r.c.f. and re-suspended in AggreWell media (Stem Cell 
Technologies) with 10 μm ROCK inhibitor (R & D Systems). Cells (1.0 x 107) were added 
to one well of an AggreWell 400ex plate and spun at 100 r.c.f. After centrifugation, the 
plates were transferred to an incubator at 37°_C. After 24 hours, the embryoid bodies were 
collected with gentle pipetting, allowed to sediment by gravity, re-suspended in DMEM/F12 
media (Gibco) with 20% Knock-out Serum Replacement (Life Sciences) and cultured in 
very low adhesion plates (Corning). After 7 days of suspension culture, doxycycline (1 μg 
ml−1) was added to the media and 3–7 days later the embryoid bodies were transferred to 
gelatin-coated plates. The media was then switched to DMEM supplemented with 10% FBS, 
100_IU_ml 1 penicillin, 100 μg_ml 1 streptomycin and 1 μgml−1 doxycycline.
Gene Expression
For the microarray experiments, RNA was collected from three biological replicates of EF+, 
EF− and EFFib cells using trizol (Life Technologies) and an RNeasy kit (Qiagen). The 
samples were then prepared for analysis and hybridized to Human Genome U133+ v2.0 
chips (Affymetrix) by the Microarray Core at Dana-Farber Cancer Institute. GenePattern 
release 3.8.0 was used to normalize the raw microarray data using the robust multichip 
average (RMA) algorithm, preprocess the normalized data using default parameters and find 
differentially expressed probe sets. Gene set enrichment analysis (GSEA) was performed 
using the GSEA platform (www.broadinstitute.org/gsea) and Enrichr (amp.pharm.mssm.edu/
Enrichr). The gene expression CEL files were deposited in the Gene Expression Omnibus 
(GEO) Repository under the accession number GSE64686. Venn diagrams were prepared 
using BioVenn (http://www.cmbi.ru.nl/cdd/biovenn/)60. Published data sets used in the gene 
expression analysis included GSE3462048 (Ewing sarcoma), GSE1482749 (osteosarcoma), 
and the Cancer Cell Line Encyclopedia46 (http://www.broadinstitute.org/ccle/home).
Statistical Analysis
Data are presented as mean ± SEM. Student’s t test was used to calculate p values. Statistical 
analyses were conducted using GraphPad Prism 5.0.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
EWS-FLI1 expression in embryoid bodies. (A) Schematic diagram illustrating the 
differentiation protocol of the human embryonic stem cells. The culture protocol consists of 
the three steps: 1) embryoid body formation under non-adherent conditions; 2) transfer of 
embryoid bodies to gelatin-coated plates; 3) monolayer culture of the cells that outgrow 
from the embryoid bodies. Doxycycline is added to the embryoid bodies after seven days of 
culture. (B) Western blot analysis showing the inducible expression of EWS-FLI1 in the 
embryoid bodies in the presence, but not absence, of doxycycline. (C) Western blot analysis 
showing the constitutive knockdown of p53 by an shRNA in embryoid bodies. Knockdown 
efficiency is not affected by doxycycline. (D) EFFib cells exhibit a morphology similar to 
fibroblast cells. (E) The EF+ cells exhibit a distinct morphology and are more rounded and 
less elongated than the EFFib cells. (F) Western blot analysis of EWS-FLI1 expression in 
Ewing sarcoma cell lines (A673 and TC32), EF+ cells and EFFib cells. The relative 
expression level of EWS-FLI1 for each cell line compared to EF+ is shown below the blot. 
(G) The growth rate of the EF+, EFFib and A673 cells was measured using trypan blue 
exclusion and cell counting. The data were fit to an exponential curve using GraphPad 
Prism. Error bars indicate the standard deviation of three replicates.
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Figure 2. 
The immunophenotype of EF+ (A) and EFFib (C) cells as determined by flow cytometry. 
Cells were labeled with APC- and PE-labeled antibodies against CD34, CD73, CD99, 
CD105, c-Kit, CD271 and isotype-matched control antibodies. The isoptype control is 
shown in black and the specific antibody is shown in red. (B) Multiparameter flow 
cytometry with EFFib and EF+ cells for CD105 and CD271. (D) FACS analysis comparing 
expression of CD99 and c-Kit in EF+ cells (red line) and EF− cells (black line), four days 
after removal of doxycycline.
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Figure 3. 
The EF+ cells exhibit oncogene addiction. (A) RT-qPCR for the EWS-FLI1 fusion in the 
EF+ cells and the EF− cells after 2, 4, and 10 days of doxycycline removal. For comparison, 
expression of EWS-FLI1 in the EFFib cells and EF stem cells is also shown. Expression of 
EWS-FLI1 is shown relative to actin expression. Error bars indicate the standard error of the 
mean of three experiments (***, p<0.001). (B) Western blot of EWS-FLI1 in the EF+ cells 
and the EF− cells after 2, 4, 6, and 10 days of doxycycline removal. (C) Growth of EF+ cells 
and EF− cells. Cell growth was measured using trypan blue exclusion and a Vi-CELL Cell 
Viability Analyzer. Error bars indicate the standard error of the mean of three experiments. 
(D) Flow cytometry analysis of EdU incorporation by EF+ cells (red line) and EF− cells 
(black line) after four days without doxycycline. (E) Flow cytometry analysis of caspase-3 
activation in EF+ cells (red line) and EF− cells (black line) after ten days without 
doxycycline. (F) Dose-response curves of EFFib, EF+, A673 (Ewing sarcoma), EW8 (Ewing 
sarcoma), U2OS (osteosarcoma) and BJ-fibroblast (non-transformed fibroblast) cells treated 
with olaparib for three days. Cell viability was measured using CellTiter-Glo luminescence. 
Data were log-transformed and normalized. Error bars indicate the standard error of the 
mean of three experiments.
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Figure 4. 
The EF+ cells exhibit properties of transformation. (A) The EFFib and EF+ cells were 
cultured for fourteen days without passaging and then colonies were stained with methylene 
blue. (B) Soft-agar assay for anchorage-independent growth of EFFib and EF+ cells. Error 
bars indicate the standard error of the mean of three experiments (*, p<0.05). (C) Lentiviral 
integration analysis. Genomic DNA was isolated from the parental stem cells and EF+ cells 
at passage 4 and 21. Integration sites were then analyzed in three digestion libraries using a 
genome walking approach.
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Figure 5. 
EF+ cells exhibit an Ewing sarcoma gene expression signature. (A) Unsupervised 
hierarchical clustering of 88 cancer cell lines, across 12 different tumor types, and the EF+ 
cells. The Ewing sarcoma cell line cluster is outlined in blue and the EF+ cell line cluster is 
outlined in red. (B) RT-qPCR of select upregulated and downregulated genes. The error bars 
indicate the standard error of the mean from three experiments. The upper panel shows 
genes that are upregulated in the EF+ cells and the lower panel shows genes upregulated in 
the EF− cells. (C and D) Gene set enrichment analysis (GSEA) shows enrichment of the 
Hancock et al. upregulated and downregulated gene sets in the gene expression data from the 
EF+ versus EF− (C) and EF+ versus EFFib (D) comparisons. GSEA plots are also shown for 
the curated gene sets RIGGI_EWING and ZHANG_TARGETS_OF_EWSR1_FLI1 from 
the MSigDB collection. The normalized enrichment scores (NES) and FDR q-values are 
shown.
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Figure 6. 
The EF+ gene sets are enriched in Ewing cell lines. (A) GSEA shows enrichment of the EF+ 
versus EF− gene set, EF+ versus EFFib gene set, and the Hancock et al. gene set in the gene 
expression data from the Ewing sarcoma cell lines versus other tumor types comparison. (B) 
Venn diagram showing the overlap between the EF+ versus EF− gene set, EF+ versus EFFib 
gene set, and the Hancock et al. gene set. (C) GSEA shows enrichment of the EF Overlap 
upregulated gene set in the gene expression data from the Ewing sarcoma cell lines versus 
other tumor types comparison. (D) GSEA shows enrichment of the EF Unique upregulated 
gene set in the gene expression data from the Ewing sarcoma cell lines versus other tumor 
types comparison. (E) GSEA shows enrichment of the Hancock et al., EF Overlap and EF 
Unique gene sets in primary Ewing sarcoma tumors, compared to primary osteosarcoma 
tumors. The normalized enrichment scores (NES) and FDR q-values are shown.
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Table 1
The most highly upregulated genes from the EF+ versus EF− and EF+ versus EFFib comparisons.
EF+ versus EF− EF+ versus EFFib
Gene Fold Change Gene Fold Change
GRP 407 RBM11 722
SYNPR 332 LIPI 455
LOC400796 324 NELL2 383
NR0B1 220 SLAIN1 371
KIAA0101 175 LOC400796 314
TRDN 166 SYNPR 313
F2RL1 144 NPY1R 310
RRM2 142 SYCP1 289
CDH12 101 OTX2 283
RBM11 99 NPY 263
KCNE3 95 GRP 239
RP11 83 NR0B1 223
PBK 81 AKR1C3 176
KIF20A 74 TRDN 173
NPY 73 EPHA3 157
DLG7 68 FLJ25076 156
TOP2A 63 APCDD1 154
CXCR7 60 NKX2-2 137
PCDH20 60 CLDN1 133
CDC2 58 HSD17B2 121
NUSAP1 55 OLFM3 119
LOC144997 51 ITM2A 114
LOC647248 51 PTGER3 107
BHLHB5 48 HOXD10 103
GAS1 46 BCL11B 95
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Table 2
Enrichment of the EF+ versus EF− upregulated gene signature in different cell lines in the Cancer Cell Line 
Encyclopedia. Enrichment was assessed using the Enrichr tool43. Ewing sarcoma cell lines are shown in bold.
Rank Cell Line P-Value Z-Score Combined Score
1 A673_BONE 1.67e-48 −1.79 185.41
2 SKNMC_BONE 3.97e-44 −1.81 169.91
3 MHHES1_BONE 3.01e-41 −1.86 162.84
4 SKES1_BONE 4.22e-38 −1.86 150.52
5 TC71_BONE 2.56e-37 −1.81 143.24
6 RDES_BONE 3.30e-33 −1.85 129.07
7 CADOES1_BONE 1.61e-18 −1.75 63.42
8 NCIH446_LUNG 2.71e-8 −1.75 22.40
9 NCIH889_LUNG 6.55e-7 −1.81 17.66
10 NCIH1092_LUNG 2.17e-6 −1.87 16.23
11 CORL47_LUNG 3.03e-6 −1.83 15.55
12 NCIH1385_LUNG 4.22e-6 −1.83 15.10
13 NCIH1184_LUNG 3.04e-6 −1.74 14.79
14 NCIH2081_LUNG 7.15e-6 −1.81 14.37
15 NCIH1930_LUNG 4.61e-6 −1.69 13.97
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